Kadimastem Granted a Patent in the US for Treatment of Neurodegenerative Diseases

Israeli biotechnology company Kadimastem, announced that it has been granted a patent from the United States Patent and Trademark Office for its technology in the field of cell based treatment for diseases of the nervous system. The United States patent joins additional patents granted in Israel and Europe.

The patent is for the innovative method of producing supporting cells in the central nervous system from stem cells, including myelin-producing cells, and it is the foundation for the company’s products in the field treatment of neurodegenerative diseases.

The technology is the fruit of the research of Professor Michel Revel, the company’s Chief Scientist, at the Weizmann Institute. The owner of the patent is Yeda Research and Development Company Ltd. According to an agreement between Kadimastem and Yeda, the company had been granted an exclusive license for exclusive use of the patent.

Kadimastem is developing innovative treatments for a number of severe diseases by transplanting cells and tissues differentiated from human stem cells. The patent expands the intellectual property coverage in the American market as part of the company’s strategy in the neurodegenerative diseases field in general and ALS in particular.

Yossi Ben-Yossef, Kadimastem’s CEO, noted: “With the company’s preparations for the first clinical trial of its unique product, the reinforcement of the company’s IP is particularly important. The United States is a target market for the company’s products for several reasons, including regulatory (the company will conduct the trial according to the outline coordinated with the FDA), strategic collaborations, potential investors and market size. The patent granted in the United States is a substantial asset in each of these aspects.”

Professor Michel Revel, the company’s Chief Scientist, added: “The granting of the patent is an international recognition of the uniqueness of the technology at the basis of the cell based treatment for ALS, which Kadimastem develops toward the upcoming clinical trial. The patent also has applications in additional nervous system diseases, and it reinforces the company’s position in the field.”